- Home
- GFL vs AXSM Comparison
GFL vs AXSM Comparison
Compare GFL & AXSM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | GFL | AXSM |
|---|---|---|
| Founded | 2007 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 13.6B | 12.0B |
| IPO Year | 2019 | 2015 |
Fundamental Metrics
Financial Performance| Metric | GFL | AXSM |
|---|---|---|
| Price | $41.49 | $215.89 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 10 | 17 |
| Target Price | $55.22 | ★ $211.12 |
| AVG Volume (30 Days) | ★ 2.2M | 657.9K |
| Earning Date | 04-29-2026 | 05-04-2026 |
| Dividend Yield | ★ 0.16% | N/A |
| EPS Growth | N/A | ★ 38.56 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $8.18 | $57.24 |
| Revenue Next Year | $7.20 | $55.88 |
| P/E Ratio | $5.95 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $33.33 | $104.56 |
| 52 Week High | $51.40 | $260.19 |
Technical Indicators
Market Signals| Indicator | GFL | AXSM |
|---|---|---|
| Relative Strength Index (RSI) | 59.90 | 45.70 |
| Support Level | $38.42 | $219.18 |
| Resistance Level | $41.75 | $236.26 |
| Average True Range (ATR) | 1.20 | 8.79 |
| MACD | 0.00 | -0.86 |
| Stochastic Oscillator | 59.79 | 38.81 |
Price Performance
Historical ComparisonAbout GFL GFL Environmental Inc. Subordinate voting shares no par value
GFL Environmental Inc is an environmental services company. Its offerings include non-hazardous solid waste management, infrastructure, soil remediation, and liquid waste management services. Its solid waste management business line, which generates the majority of the revenue, consists of the collection, transportation, transfer, recycling, and disposal of non-hazardous solid waste. Its Environmental Services business line includes liquid waste and soil remediation. The company's geographical segments are Canada and the United States. The company derives the majority of its revenue from the United States.
About AXSM Axsome Therapeutics Inc.
Axsome Therapeutics Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapies for the management of the central nervous system, or CNS, disorders for which there are limited treatment options. Its pipeline products include AXS-05, AXS-07, AXS-12, and AXS-14. It manages its business as one operating segment and reporting unit, which is the business of developing and delivering novel therapies for the management of CNS disorders.